<DOC>
	<DOCNO>NCT01433731</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability topical SHP141 apply directly skin lesion patient Stage IA , IB , IIA Cutaneous T-cell Lymphoma . This study also investigate effect SHP141 skin lesion patient Stage IA , IB , IIA CTCL .</brief_summary>
	<brief_title>Safety , Pharmacodynamics ( PD ) , Pharmacokinetics ( PK ) Study SHP141 1A , 1B , 2A Cutaneous T-Cell Lymphoma ( CTCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Histopathologically confirm CTCL ; document verifiable biopsy report require . Documented clinical Stage IA , IB , IIA CTCL . Skin lesion involvement least 3 % BSA accessible topical application study drug biopsy . ECOG performance status 02 . CTCL histologic evidence folliculotropic variant large cell transform CTCL . Severe pruritus require systemic topical treatment . Palpable lymph node â‰¥1.5 cm diameter ( unless lymph node biopsied designated Stage IAIIA disease ) . Coexistent second malignancy history prior solid organ malignancy within previous 5 year ( exclude basal squamous cell carcinoma skin , situ carcinoma cervix ( CIN 3 ) , papillary follicular thyroid cancer treat curatively , prostate cancer treat curatively ) . Any prior history hematologic malignancy ( CTCL ) . History current major renal , hepatic , gastrointestinal , pulmonary , cardiovascular , genitourinary hematological disease , CNS disorder , infectious disease coagulation disorder determine Investigator . Evidence active Hepatitis B C HIV . Circulating atypical cell &gt; 5 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>CTCL</keyword>
	<keyword>Cutaneous T-Cell Lymphoma</keyword>
</DOC>